Mymetics Corp (MYMX)

[bow-tie]

Posted May 31st 2021
POSITIVE OUTCOME OF EUROPEAN DECENTRALISED REGISTRATION PROCEDURE FOR STALLERGENES GREER’S SUBLINGUAL HOUSE DUST MITE ALLERGEN IMMUNOTHERAPY TABLET

Stallergenes Greer announces the positive outcome of the European decentralised registration procedure for its sublingual house dust mite (HDM) allergen immunotherapy tablet Actair®.

The Paul-Ehrlich-Institut (PEI), Germany, acted as reference member state on behalf of 21 European countries. Each member state involved in the procedure will now issue individual national marketing authorisations at the end of their national phase.

“We are pleased to have achieved this significant milestone which demonstrates our commitment to patients and marks a major step forward for the company’s further development in the European market. Stallergenes Greer’s sublingual allergen immunotherapy tablet is an important option for people suffering from house dust mite-induced allergic rhinitis or rhinoconjunctivitis and illustrates our engagement to provide patients with a range of administration modes tailored to individual needs and profiles,” declares Michele Antonelli, Chief Executive Officer.
https://www.stallergenesgreer.com/positive-outcome-european-decentralised-registration-procedure-stallergenes-greers-sublingual-house#